CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

CASI Pharmaceuticals (NASDAQ:CASI), a clinical-stage biopharmaceutical company, will present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO David Cory will deliver a company update on September 8, 2025 at 10:00 AM ET. The company, which focuses on developing therapies for organ transplant rejection and autoimmune diseases, will also conduct one-on-one meetings with investors during the conference.

News Market Reaction – CASI

+1.30%

+1.30% Session close to close

In the Sep 3 session, CASI gained 1.30%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27^th Annual Global Investment Conference on September 8, 2025 at 10:00 AM ET.

CASI will also host one-on-one meetings with investors at the conference.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.

More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:

Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com

SOURCE: CASI Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

When is CASI Pharmaceuticals presenting at the H.C. Wainwright Conference?

CASI Pharmaceuticals will present on September 8, 2025 at 10:00 AM ET.

Who will present CASI Pharmaceuticals' company update at the H.C. Wainwright Conference?

David Cory, CEO of CASI Pharmaceuticals, will present the company update.

What therapeutic areas does CASI Pharmaceuticals focus on?

CASI Pharmaceuticals focuses on developing innovative therapies for organ transplant rejection and autoimmune diseases.

Will CASI Pharmaceuticals offer investor meetings at the H.C. Wainwright Conference?

Yes, CASI Pharmaceuticals will host one-on-one meetings with investors at the conference.